跳至主要内容
临床试验/NCT00133627
NCT00133627已完成4 期

Safety and Efficacy Comparison Ketotifen Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis

Novartis1 个研究点 分布在 1 个国家目标入组 229 人开始时间: 2005年4月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Novartis
入组人数
229
试验地点
1

研究概览

简要总结

Medications available for the treatment of seasonal allergic conjunctivitis include antihistamines. These medicines block the release of histamine, a substance in the body that is released when an allergic reaction occurs. Novartis (NVS) has developed an eye drop formulation of a well tried antihistamine called ketotifen. This study will compare the efficacy and the tolerability of ketotifen eye drops with emedastine, which is a popular treatment for seasonal allergic conjunctivitis in China.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
3 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 3 years or older.
  • History of seasonal allergic conjunctivitis
  • Presence of bilateral ocular itching/conjunctival hyperaemia (redness) at baseline:
  • at least intensity degree 2 for itching, and
  • at least intensity degree 4 for composite score of itching and conjunctival hyperaemia

排除标准

  • Other systemic/ophthalmic conditions
  • Presence of any form of allergic conjunctivitis other than seasonal allergic conjunctivitis (e.g. perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, giant papillary conjunctivitis).
  • Active bacterial or viral conjunctivitis or history of ocular herpes.
  • Presence or history of severe dry eye.
  • Previous treatments
  • Any systemic or ocular corticosteroids within two (2) weeks prior to randomization.
  • Any systemic or ocular mast cell stabilizers within two (2) weeks prior to randomization.
  • Any other ophthalmic medication within three (3) days prior to randomization.
  • Other protocol-defined inclusion/exclusion criteria may apply

研究者

发起方
Novartis
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验